Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
NCT: NCT02977299 · COMPLETED
Brief Summary
This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy (ADT). Adequate ADT is defined as a therapeutically sufficient dose for a sufficient treatment period, which would be expected to be effective as listed in the MGH Antidepressant Treatment Response Questionnaire (ATRQ). Patients will be randomized in a 1:1:1 fashion to one of three open-label treatment arms: a) aripiprazole augmentation, b) rTMS augmentation, and c) switching to venlafaxine XR or Duloxetine.
Frequently Asked Questions
What is Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD?
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD is a clinical trial registered under NCT02977299. Current status: COMPLETED.
What is the status of NCT02977299?
The current status of NCT02977299 (Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD) is: COMPLETED.
When did Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD start?
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD started on 2017-07-13.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.